View More Recent Stories
-
Jones Trading Starts Intellia Therapeutics (NTLA) at Buy
-
Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital
-
Intellia Therapeutics (NTLA) Misses Q2 EPS by 30c
-
BMO Capital Reiterates Outperform Rating on Intellia Therapeutics (NTLA)
-
Intellia Therapeutics (NTLA) Announces CFO Transition
-
Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA)
-
Intellia Therapeutics (NTLA) Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
-
Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
-
Truist Securities Reiterates Buy Rating on Intellia Therapeutics (NTLA)
-
Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'
-
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
-
Intellia Therapeutics (NTLA) Appoints Brian Goff to its Board
-
RBC Capital Reiterates Outperform Rating on Intellia Therapeutics (NTLA)

